GSK Buys Stiefel in $3.6 Billion Deal

April 20, 2009
Stiefel manufactures anti-itching creams, acne treatments and other skin care products.

British pharmaceutical giant GlaxoSmithKline said on April 20 that it has agreed to buy U.S.-based Stiefel Laboratories in a deal worth up to $3.6 billion dollars.

"GSK and Stiefel Laboratories today announced that they have signed an agreement to create a new world-leading specialist dermatology business," the pair said in a joint statement.

The deal for Stiefel, a maker of anti-itching creams, acne treatments and other skin care products, had been widely expected.

Copyright Agence France-Presse, 2009

Popular Sponsored Recommendations

Smarter Savings for Manufacturers - Guide

Sept. 12, 2023
Enhance your service experiences and boost revenue while reducing costs. Learn how one platform can help your business be more agile and productive in today's market.

Navigating Disruption: A Leader’s Guide to Strategy Under Uncertainty

Nov. 1, 2023
AI, sustainability, digital--industrials are facing disruptive forces that are redefining what it takes to win. What got your company where it is today won’t get you where you...

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

Disruptive EV Technologies Are Driving New Supplier Realities

Sept. 20, 2023
Vehicle electrification is upending the automotive landscape, forcing suppliers to make critical strategic and operational decisions. Understand what that means for you in our...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!